Join Asia’s shared services and GBS community for AI insights, sponsor-led sessions and networking, 20–23 October 2026.

SINGAPORE, Sept. 14, 2026 /PRNewswire/ — With five weeks to go, the 29th Asian Shared Services & Outsourcing Week (SSOW) will bring shared services and Global Business Services (GBS) leaders to One Farrer Hotel, Singapore, from 20–23 October 2026 to explore AI adoption, workforce transformation and the future of GBS operating models.

Organised by the Shared Services and Outsourcing Network (SSON), the conference will bring together industry insights, practical learning and peer networking to explore how GBS organisations can scale AI adoption, prepare their workforce and deliver value beyond cost savings.

Explore the SSOW Asia 2026 Agenda here.

From AI Adoption to Workforce Transformation

This year’s programme will feature perspectives from industry leaders on putting AI into practice and preparing GBS teams for change. Highlights include:

Kris Kabasinskas, Partner and Asia Pacific Operate Center of Excellence Lead at Deloitte, will present “AI as the GBS Value Engine,” examining how AI-driven operating models can support enterprise transformation.

Annie Wong, Vice President of Quote to Cash Operations APAC & Japan at IBM, will lead a session within the SSON Bootcamp: Agentic AI in Shared Services, addressing implementation at scale and the redesign of roles for human–AI collaboration.

In the opening keynote, “Transforming a 30,000-Person GBS Workforce into a Skills-Powered Global Capability Centre,” Daniel Blackburn, Global Head of HR, Workforce Transformation at Standard Chartered, will share approaches to reskilling, internal mobility and aligning workforce capabilities with business needs.

Raghavendra Reddy, Co-Founder & Chief Operating Officer of Bluecopa, will lead the interactive roundtable “Finance 2030: The Future of Automated, AI-Powered Finance Functions,” inviting delegates to discuss how AI and automation could reshape finance operations.

Shared Services Networking in Singapore

Dedicated networking sessions and informal networking breaks will connect delegates with GBS practitioners, speakers and solution providers. Attendees can exchange transformation experiences, forge partnerships and turn fresh insights into action within their organisations.

Register for the 29th Asian Shared Services & Outsourcing Week.

About SSON

Established in 1999, the Shared Services and Outsourcing Network (SSON) is a global community of shared services, GBS and outsourcing professionals. Part of IQPC, SSON provides news, research, benchmarking, events and professional development through SSON Digital, SSON Research & Analytics, SSON Events, and GBS Training & Certification.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/singapore-to-host-shared-services-leaders-at-29th-asian-shared-services–outsourcing-week-2026-this-october-302875400.html

SOURCE Shared Services and Outsourcing Network (SSON)

Sustained profitability, industry leading performance, and tech driven automation position Hong Kong’s digital trade finance leader for its next phase of expansion.

HONG KONG, Sept. 13, 2026 /PRNewswire/ — Qupital, Asia’s leading AI-driven fintech platform specializing in cross border e-commerce trade finance, today announced US$300 million in combined new capital commitments, anchored by its Series C funding round. The financing is led by prominent Asia-headquartered asset manager M Capital, alongside additional ABS commitments from Mitsubishi UFJ Financial Group (MUFG) and Quester Capital.

With tens of thousands of enterprises served, cumulative loans processed by Qupital have surpassed US$9.5 billion. The new capital will expand Qupital’s financing capabilities across China, the US, Japan, and Southeast Asia, while further scaling its proprietary AI risk engine and maintaining exceptional credit performance.

Profitable Growth Driven by Tech Automation

The financing comes on the heels of continuous operational excellence, with Qupital compounding profitability over the past two years. By leveraging real-time sales and operational data from merchants selling on leading global marketplaces including Amazon, TikTok Shop, TMall, and JD.com, Qupital’s automated risk engine drives agile underwriting, delivering high operational leverage and rapidly expanding profit margins.

“Double digit year-on-year growth in cross-border e-commerce drives an unprecedented trillion-dollar liquidity gap, and this Series C round puts Qupital in prime position to bridge it. We are capturing this massive wave head on to build the core financial infrastructure for global e-commerce to support underserved SMEs.”
— Andy Chan, Co-Founder & President of Qupital

“Agentic commerce and social e-commerce are redefining the speed of global trade. AI automation addresses traditional underwriting time lags to deliver higher efficiency and flexibility, and processes massive datasets, which are beyond human capability, to refine credit decisions. Converting live transactional data into instant trade credit is no longer just an advantage, it is the baseline for the future of digital commerce.”
— Winston Wong, Co-Founder & CEO of Qupital

Strategic Roadmap Toward Capital Market Milestones

Proceeds from this milestone capital raise will be deployed to expand Qupital’s loan pool to serve high growth e-commerce businesses globally, while simultaneously accelerating AI R&D and proprietary technology development. By harnessing its AI risk engine and credit automation, Qupital expects its profit margins to expand to over 45% within the next twelve months. The company is now actively exploring capital market opportunities including IPO, fundraising and strategic acquisition to scale operations and optimize capital structure.

About Qupital

Qupital is Asia’s leading fintech platform specializing in data driven financing solutions for digital businesses. Headquartered in Hong Kong, Qupital empowers e-commerce businesses trading on platforms including Amazon, JD.com, Tmall, TikTok Shop, and Pinduoduo, with working capital. As the first platform in Asia to securitize e-commerce merchant loans, Qupital pairs industry leading credit performance and sustained profitability with backing from global financial institutions and strategic investors, including Alibaba, MindWorks Capital, Greater Bay Area Homeland Development Fund, and Innovation and Technology Ventures Fund of the Hong Kong SAR Government.

About M Capital

Based in Hong Kong, M Capital Group (“M Capital”) is a financial services group with global reach. Driven by the firm’s philosophy to excellence, M Capital is committed to serve its clients to its highest standards. M Capital strives to be a leading alternative asset management company in Hong Kong, helping professional investors, including but not limited to, high net worth individuals, family offices, financial institutions, corporations, and offshore funds to generate long-term sustainable risk-adjusted returns.

View original content:https://www.prnewswire.com/apac/news-releases/qupital-raises-300m-in-series-c-led-by-m-capital-and-new-mufg-abs-financing-eyes-overseas-markets-and-ipo-302876994.html

SOURCE Qupital

SHANGHAI, Sept. 14, 2026 /PRNewswire/ — Shanghai Electric (SEHK: 02727, SSE: 601727) has achieved a milestone in the high-end overseas energy sector by securing the contract for Unit 3 of the Sarawak Samalaju Combined Cycle Gas Turbine (CCGT) Project in Malaysia. The win represents significant international recognition of Shanghai Electric’s heavy-duty gas turbine technology, underscoring the company’s growing competitiveness in the global gas turbine market.

Under the agreement, Shanghai Electric will deliver a full EPC turnkey solution for the gas-fired power plant, coupled with a 25-year long-term service agreement (LTSA) covering all major equipment. Notably, every core component—from gas turbines and steam turbines to generators, heat recovery steam generators, and air-cooled systems—will be manufactured in-house by Shanghai Electric, which will also serve as the sole provider of the long-term maintenance and service program. This integrated, end-to-end capability gives Shanghai Electric full life-cycle coverage, spanning equipment manufacturing, systems integration, and multi-decade operational support—a vertical model that brings the company on par with the established global leaders in the heavy-duty gas turbine sector.

Shanghai Electric’s current heavy-duty gas turbine lineup features two principal models, with output ratings of 300 MW and 78 MW, respectively. To date, the company has delivered 103 units, with total installed capacity from commissioned projects exceeding 21,000 MW. The units covered by Shanghai Electric’s long-term service and maintenance programs have accumulated more than 1.3 million operating hours. With robust production capacity available across both turbine classes, Shanghai Electric is positioned to offer new units for delivery as early as 2028. Beyond the Malaysian energy developer that awarded the current contract, project developers in Indonesia, Thailand, the Philippines, and Vietnam have also expressed strong interest in placing orders.

SOURCE Shanghai Electric

COLORADO SPRINGS, Colo., Sept. 14, 2026 /PRNewswire/ — Auria, a leading provider of advanced space, missile, and cyber solutions, today announced a partnership and contract with Mitsubishi Electric Corporation to deliver next-generation satellite communications capabilities through Auria’s advanced Kythera Operating System mission and resource management and optimization software.

Through the partnership, Auria will provide software to dynamically and autonomously manage, optimize, and orchestrate payload and network resources for Mitsubishi Electric’s next-generation, software-defined SATCOM satellites. The effort will leverage Auria’s Kythera Operating System (KOS), part of Auria’s HeliOS product line, to enable autonomous satellite service provisioning, real-time resource optimization, orchestration of space and ground assets, and adaptive mission operations in response to changing demand, operating conditions, and interference events.

“Mitsubishi Electric has a long history of advancing space technology, and we are proud to empower their innovation in dynamic, autonomous satellite communications,” said Damian DiPippa, CEO at Auria. “By combining Mitsubishi Electric’s advanced software-defined satellite hardware with Auria’s software for dynamic resource management and mission optimization, we are enabling Mitsubishi Electric customers to leverage higher capacity and more flexible, resilient, responsive, and efficient SATCOM services.”

Auria will also provide its KOS Interference Manager module, a HeliOS capability that dynamically detects, geolocates, and mitigates signal interference. Together, these capabilities help satellite operators maintain high-quality, resilient service while adapting to changing operating conditions and mission needs.

The partnership with Mitsubishi Electric reflects Auria’s growing role in delivering intelligent software systems for complex space operations. Auria’s HeliOS platform is designed to serve as a software mission segment system for advanced SATCOM architectures, providing the Space Brain® needed to autonomously provision service, optimize resources, and support resilient communications across dynamic operating environments.

“This partnership is about marrying Mitsubishi Electric’s advanced satellite systems with the intelligent software needed to manage and optimize them,” said Andy Musliner, SVP Growth at Auria. “As SATCOM architectures become more capable and complex, satellite manufacturers and their operator customers need systems that can adapt on the fly, manage resources autonomously, and mitigate interference in real time. That is exactly where Auria’s HeliOS product line and its Kythera Operating System deliver value.”

Mitsubishi Electric has been a pioneer in Japanese space technology since the 1960s and has contributed to a broad range of satellite programs and space systems. This partnership underscores the importance of software-defined, autonomous mission management as satellite communications systems continue to evolve.

About Auria

Auria Space delivers technology solutions for next-generation space, satellite, and mission systems. The company’s mission is to simplify and modernize command, control, and communications (C3) to unify space and ground operations, deliver resilient connectivity from orbit to the tactical edge, and automate secure mission intelligence. Combining commercial off-the-shelf technologies with mission-focused engineering, Auria helps government and commercial customers accelerate deployment, reduce lifecycle costs, increase agility, and securely integrate satellite constellations, ground networks, and edge systems amid rapidly evolving threats and mission demands.

About Mitsubishi Electric Corporation

Guided by its corporate philosophy, Mitsubishi Electric Corporation (TOKYO: 6503) places sustainability at the core of its operations and values stakeholder trust—encompassing society, customers, shareholders and employees. In pursuing profitability, capital efficiency and growth, Mitsubishi Electric works closely alongside customers to develop value-added solutions that address today’s complex challenges while enhancing the company’s sustainable corporate value. Founded in 1921, Mitsubishi Electric has over a century of experience in delivering reliable, high-quality products and solutions. With over 200 group companies and approximately 150,000 employees worldwide, the company is a recognized global leader in manufacturing, marketing and selling electrical and electronic equipment and systems across a broad range of sectors, including public utility systems, energy systems, defense and space systems, factory automation systems, automotive equipment, building systems, air conditioning systems & home products, digital innovations, and semiconductor & devices. Mitsubishi Electric recorded consolidated revenue of 5,894.7 billion yen (U.S.$ 36.8 billion*) in the fiscal year that ended on March 31, 2026. For more information, please visit www.MitsubishiElectric.com

*JPY 160=USD 1, the approximate rate on the Tokyo Foreign Exchange Market on March 31, 2026

CONTACT: Dan Palumbo
[email protected]

View original content:https://www.prnewswire.com/apac/news-releases/auria-announces-partnership-and-contract-with-mitsubishi-electric-to-advance-next-generation-satcom-mission-and-resource-management-302876578.html

SOURCE Auria Space

 7-Eleven Philippines becomes the latest retailer to join RELEX’s global customer network

MANDALUYONG CITY, Philippines, Sept. 14, 2026 /PRNewswire/ — Philippine Seven Corporation (PSC), the exclusive operator of 7-Eleven convenience stores in the Philippines, is now utilizing forecasting and replenishment from RELEX Solutions, provider of unified supply chain and retail planning solutions, to transform planning across its 27 distribution centers (DCs). The implementation, delivered in partnership with genieX, has combined RELEX’s world-class technology with genieX‘s business consultancy, project management, and local market expertise to optimize PSC’s end-to-end supply chain.

7-Eleven is the world’s largest convenience store chain, with over 83,000 outlets in 17 countries. In the Philippines, PSC oversees all 7-Eleven operations nationwide. By implementing RELEX’s forecasting and replenishment capabilities, PSC will replace its spreadsheet-based processes with automated, data-driven planning to improve supplier collaboration, increase fill rates, and upgrade operational efficiency.

“For over four decades, PSC has worked to make 7-Eleven a trusted part of everyday life for Filipinos,” said Victor Paterno, Chair of Philippine Seven Corporation. “As we continue to expand and digitalize, partnering with RELEX and genieX enables us to strengthen our supply chain foundation and plan more effectively for the future.”

RELEX and genieX will work closely with PSC to ensure a smooth implementation and continuous support throughout the project.

“7-Eleven is one of the most recognizable brands in the Philippines,” said Mahesh Gopinath, Chief Operating Officer at genieX. “We’re proud to support PSC in implementing RELEX’s advanced forecasting and replenishment solution. Together, we’ll help drive efficiency, accuracy, and resilience across their supply chain.”

The RELEX forecasting and replenishment capabilities enable more accurate and agile demand planning by leveraging multiple data sources while accounting for seasonality and local fluctuations. In addition, RELEX provides DC-level visibility and precise replenishment recommendations, helping retailers, like PSC, reduce manual work, optimize inventory, and improve service levels.

“We’re delighted to welcome Philippine Seven Corporation to the RELEX customer community,” said Rod Talbot, Vice President of Sales, APAC at RELEX Solutions. “We look forward to helping PSC achieve similar results across the dynamic and diverse Philippine market.”

About Philippine Seven Corporation

Philippine Seven Corporation (PSC) is the exclusive licensee, developer, and operator of 7-Eleven stores in the Philippines. Founded in 1982, the company revolutionized the local retail landscape by introducing the modern convenience store concept to the country.

About RELEX Solutions

RELEX Solutions delivers a unified supply chain planning platform for retailers and manufacturers, enabled by proven AI technology. We help companies optimize demand forecasting, replenishment, merchandising, pricing and promotions, supply chain operations, and production planning across the end-to-end value chain. Brands like ADUSA, AutoZone, Coles, Circle K, Dollar Tree and Family Dollar, Ford South America, M&S Food, PetSmart, Rituals, The Home Depot, Systemair and Vita Coco trust RELEX to increase product availability, boost sales, deliver actionable insights, improve sustainability, and drive profitable growth.

Learn more at: https://www.relexsolutions.com/customers/

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/philippine-seven-corporation-selects-relex-to-improve-forecasting-302876416.html

SOURCE RELEX Solutions

Demand for multi-venue competition grows in South Korea to prevent ‘blind trading’ during U.S. overnight session

CHICAGO and SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ — Bruce Markets, which operates the overnight U.S. equities trading venue Bruce ATS, today announced that Meritz Securities, a leading Korean investment bank and broker-dealer, has connected to Bruce ATS’ market data feed for overnight U.S. equities. The integration provides Meritz Securities with greater visibility into quote and trade activity on Bruce ATS throughout the 8:00 p.m. – 4:00 a.m. ET overnight U.S. session, broadening customers’ view of U.S. equity prices during the Korean business day.

The milestone comes as South Korean traders fight ‘blind trading’ and reassert their role as one of the most important sources of overnight U.S. equity demand:

• Korean brokerages resumed daytime access to U.S. stocks in November 2025 following a 15-month suspension, with stronger safeguards and a multi-venue framework.
• Bruce Markets analysis found that total overnight notional activity nearly doubled between the November reopening and March 2026.
• Since November 2025, several venue-specific symbol restrictions have reinforced the importance of multi-venue competition. Multiple trading venues help Korean retail traders access pricing data and avoid ‘blind trading’ – a need underscored in September when one venue halted trading in five symbols that collectively averaged 15+ million daily shares in August.

“Healthy markets are built on competition, transparency and choice. Bruce’s share of reported overnight volume nearly doubled in Q2 because market participants increasingly recognize the value of having more than one credible source of liquidity and data,” said Jason Wallach, CEO of Bruce Markets. “Meritz Securities’ connection brings a more complete view of the overnight session in U.S. equities to one of its most important investor bases. That visibility is essential if Korean firms are going to prevent blind trading and deliver the high-quality experience customers deserve.”

Meritz Securities’ connection to Bruce ATS market data reflects accelerating growth in overnight U.S. equities. Across the three leading overnight ATSs, Q2 trading reached 11.14 billion shares and $391.2 billion in notional value – increases of 34% and 59% from Q1, respectively – according to the Bruce Q2 Overnight Market Review.

Bruce ATS accelerated significantly in Q2, with executed volume up 144% to 1.16 billion shares and executed notional up 105% to $49.03 billion. The momentum has continued into September, with Bruce’s share of reported overnight notional climbing from 14.13% to a record 20.77%, and its share of monthly overnight volume rising from 11.66% to 16.4%.

“Meritz Securities is pleased to expand Korean investors’ access to the U.S. overnight equity market through Bruce ATS,” Meritz Securities said in a statement. “This collaboration reflects our commitment to providing clients with broader market access and a stable, reliable trading experience across extended trading hours.”

As Korean demand for U.S. equities continues to expand, a competitive, multi-venue ecosystem ensures market resilience and gives brokers, traders and liquidity providers multiple pathways to see and reach liquidity across a wider range of market conditions.

About Bruce Markets
Bruce Markets operates Bruce ATS™, a U.S. equities alternative trading system enabling overnight trading from 8:00 PM to 4:00 AM ET. Underpinned by exchange-grade technology and market rules, led by industry veterans and backed by leading firms from across the trading ecosystem, Bruce provides a high-performance, resilient venue that bridges the U.S. after-hours and pre-market sessions. By providing a credible source of after-hours liquidity for brokers and investors and leading the evolution of always-available markets, Bruce brings needed competition to the ecosystem and is redefining after-hours trading worldwide. To learn more, visit www.brucemarkets.com.

About Meritz Securities
Meritz Securities Co., Ltd. is a South Korean financial services firm and member of Meritz Financial Group. The company provides securities brokerage, investment banking, sales and trading, and other financial services to retail, institutional and corporate clients. Meritz continues to expand its retail and global investing capabilities through technology-led platforms that bring together trading, information, analysis and investor communities. To learn more, visit home.imeritz.com.

Media Contacts
Forefront Communications for Bruce Markets
[email protected] 

Meritz Securities
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/meritz-securities-connects-to-bruce-markets-data-feed-for-us-equities-improving-market-data-for-korean-traders-302876583.html

SOURCE Bruce Markets

Gen Precision expands the GTK-OSI1 for production-line inspection of FAUs with up to 80 channels and custom structures, delivering 3σ ≤ 0.1 μm repeatability.

TAOYUAN, Sept. 14, 2026 /PRNewswire/ — Gen Precision is expanding its inspection capabilities for co-packaged optics (CPO) applications as manufacturers seek higher-precision, more flexible inspection of fiber array units (FAUs) and related components. The company now supports FAU configurations with up to 80 channels and custom components with specialized structures, while helping customers deploy these inspection capabilities on production lines to accelerate product qualification and production ramp-up for next-generation optical communications products.

“Passive optical components have traditionally followed standard 1×M or M×N array formats, but AI infrastructure is driving higher-density and increasingly customized designs,” said Jacky Chang, Executive Vice President and Special Assistant to the Chairman at Gen Precision. “Inspection must evolve with these products. By adapting our inspection methods to different designs and validating them with actual customer samples, we help customers advance new optical products with greater confidence.”

Gen Precision has completed inspection and validation projects for multiple customers, including non-standard custom designs, and has shipped its first batch of automated inspection systems.

GTK-OSI1 Expands FAU Inspection to Specialized Structures

Gen Precision has expanded the capability of the GTK-OSI1 Automated Passive Optical Component Inspection Machine beyond standard FAU-related component inspection, adding support for custom components and production-line deployment. By combining AOI-based precision measurement, automation control, AI-powered visual recognition, and software development capabilities, Gen Precision can adapt the system to different component designs.

The GTK-OSI1 delivers measurement repeatability of 3σ ≤ 0.1 μm for Fiber Arrays (FA), V-Grooves, and MT/MMC ferrules. Based on customer sample validation, measurement scripts and fixtures can be customized for deployment in automated production-line workflows. Once specifications are confirmed, Gen Precision can complete system customization and delivery within 6 to 8 months.

From Component Inspection to CPO Performance Validation

Gen Precision will further extend its optical communications automation capabilities into post-packaging performance testing. In collaboration with Lintes Technology, Gen Precision will develop a CPO test system to validate the performance of packaged products integrating an Optical Engine and FAU. Drawing on its expertise in precision machining, metrology, and automation, the initiative will extend Gen Precision’s capabilities beyond component-level dimensional inspection to include post-packaging performance validation, supporting customers across a broader range of optical product development stages.

About Gen Precision

Established in 1992 and headquartered in Taoyuan, Taiwan, Gen Precision offers fully integrated in-house capabilities in nanoscale precision mold manufacturing, automation system development, and injection molding.

Backed by an ISO 9001–certified quality management system, we deliver key components and integrated automation solutions for semiconductor, optical communications, healthcare, and electronics industries. With long-term global partnerships and customized support, we help customers optimize operations, improve yield, and create lasting value at scale.

Learn more at gentk.com or follow us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cpo-design-evolution-drives-gen-precisions-expansion-of-custom-fau-inspection-for-production-lines-302876259.html

SOURCE Gen Precision

• Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer).
• Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients.
• FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®.
• Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”).

MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or ¹⁸F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).

Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

PET imaging with floretyrosine F 18 (FET-PET) is recommended in international clinical practice guidelines for the imaging of gliomas, including NCCN Guidelines®^[1], but until now there has not been an FDA-approved product available in the U.S.

Gliomas are the most common form of central nervous system (CNS) cancer, accounting for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors^[2]. In the U.S., approximately 24,000 new glioma cases are diagnosed each year^[3], representing a significant unmet addressable need.

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients.”

Kelly Sitkin, President and CEO, American Brain Tumor Association, said, “The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA’s decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics.”

Patrick Wen, MD, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, said, “Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning.”

About Pixclara (floretyrosine F 18)

Pixclara® is an intravenous positron emission tomography (PET) imaging drug for the differentiation of recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. It comprises a small molecule targeting compound labeled with a diagnostic radioisotope, fluorine-18. After administration into the bloodstream, Pixclara targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner. Pixclara (TLX101-Px) is also the subject of a Phase 3 registrational study for potential indication expansion for the diagnosis of brain metastases^[4].

Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer).

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. 

Telix’s commercial franchise is anchored by its precision diagnostics portfolio: Illuccix® (kit for the preparation of gallium-68 gozetotide injection), commercially available in 22 countries including the U.S., and Gozellix® (kit for the preparation of gallium-68 gozetotide injection), approved by the U.S. Food and Drug Administration (FDA) for prostate imaging, and Pixclara® (floretyrosine F 18) approved by the FDA for glioma imaging. The Company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx (lutetium-177 (¹⁷⁷Lu) rosopatamab tetraxetan) in prostate cancer, TLX101-Tx (¹³¹I-iodofalan) in recurrent glioblastoma, and TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan) in kidney cancer, additionally complemented by a deep pipeline of next generation candidates. TLX591-Tx, TLX101-Tx and TLX250-Tx have not received marketing authorizations in any jurisdiction.

Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/fda-approves-telixs-brain-cancer-imaging-drug-pixclara-302877069.html

SOURCE Telix Pharmaceuticals Limited